oral retatrutide drops Side Effects: What Patients Should Know Retatrutide—A Game Changer in Obesity

Continuing daily dosing after the body has responded increases side effect risk without meaningful additional benefit

+

GLP-1-GIP co-agonist tirzepatide was approved by the US Food and Drug Administration in 2022 for the treatment of T2DM (Nogueiras et al., 2023)

Both are legitimate, both prescribe real GLP-1s, and both ship to your door

Melanotan 1 (MT-1) isnt authorised as a medicine by the HPRA

A study that followed 1,156 patients with severe obesity for 12 years found those who underwent gastric bypass surgery at the beginning of the study maintained an average weight loss of 35 kg while those who did not have surgery maintained an average weight loss of 02.9 kg